Report links interest in Teva's generics assets from Novartis and Mylan

The assets of Israeli drugmaker Teva Pharmaceutical International (NYSE: TEVA) in the UK, Ireland and Iceland) have attracted interest from bidders including Netherlands-incorporated Mylan (Nasdaq: MYL) and Swiss pharma giant Novartis (NOVN: VX), Bloomberg reports.

Insiders quoted by Bloomberg report that private equity firms Apollo Global Management and Cinven are also weighing up making bids for the business, which could cost $1.5 billion to $2 billion.

It is understood that the European Commission would prefer the assets to go to a buyer with experience in Europe’s generics market.